Decline in serum levels of TC, triglycerides, and low-density lipoprotein-cholesterol, with an increase in serum high-density lipoprotein-cholesterol levels; reduced levels of hepatic HMG-CoA reductase
(i) Decrease the mRNA expression levels of monocyte chemoattractant protein-1 and nuclear factor-kappaB/p65 in the aorta wall after 8 weeks of treatment in rabbits and regulate the blood lipid profile
(ii) Enhance transcriptional activation of the LXRalpha gene promoter, subsequently upregulated of ABCA1 and ABCG1, and inhibit NF-kappaB DNA binding activity
(iii) Reduce the gene expression of some inflammatory factors, such as integrins, IL-18, IL-1beta, and matrix MMP-2 and MMP-9, increase the expression of IkappaBalpha, and attenuate the expression of NF-kappaB/p65
(ii) Increase the effect of calcium pump on the membrane of sarcoplasmic reticulum, decrease the myocardial intracellular Ca2+, and reduce the mass of the left ventricular muscle